We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

This study has been terminated.
(The study was terminated on 21-Sept-2011 due to the emergent safety concern of sensory symptoms.)
ClinicalTrials.gov Identifier:
First Posted: December 17, 2010
Last Update Posted: October 12, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
This study will examine whether a single dose of PF-05230901 is safe and well tolerated when given to healthy volunteers by injection under the skin. An additional objective is to measure the blood concentrations of PF-05230901. Each dose will be tested in a different group of subjects starting from the lowest dose.

Condition Intervention Phase
Cachexia Drug: PF-05230901 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1 Ascending Single Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05230901 Administered Subcutaneously To Healthy Subjects

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Incidence and severity of adverse events. [ Time Frame: 35 days ]
  • Incidence and severity of clinical laboratory abnormalities. [ Time Frame: 35 days ]
  • Mean change from baseline in vital signs. [ Time Frame: 35 days ]
  • Mean change from baseline in 12-lead electrocardiogram (ECG) parameters. [ Time Frame: 35 days ]
  • Incidence and severity of findings during the neurological examination. [ Time Frame: 35 days ]

Secondary Outcome Measures:
  • Plasma concentrations [ Time Frame: 14 days ]
  • Anti-drug antibodies [ Time Frame: 35 days ]
  • Appetite and food consumption [ Time Frame: 13 days ]

Enrollment: 44
Study Start Date: November 2010
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dose
6 treated, 3 placebos
Drug: PF-05230901
Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
Other Name: TAM-153
Drug: PF-05230901
Single dose SC
Other Name: TAM-163


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subjects

Exclusion Criteria:

  • History of seizures, including childhood seizures.
  • History of movement disorders or related neurological conditions.
  • History of head trauma associated with loss of consciousness.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01262690

United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01262690     History of Changes
Other Study ID Numbers: B2291001
TAM-163 FIH Study; 3279K1-1000
First Submitted: November 23, 2010
First Posted: December 17, 2010
Last Update Posted: October 12, 2011
Last Verified: October 2011

Keywords provided by Pfizer:
First-in-human (FIH)
Single Ascending Dose (SAD) Study

Additional relevant MeSH terms:
Wasting Syndrome
Weight Loss
Body Weight Changes
Body Weight
Signs and Symptoms
Metabolic Diseases
Nutrition Disorders